Mimpara
Submitted by Anonymous (not verified) on 3 June 2026 - 14:53
Mimpara
Concept paper on the development of a reflection paper on the use of External controls for evidence generation in regulatory decision-making
Submitted by Anonymous (not verified) on 3 June 2026 - 14:42
Concept paper on the development of a reflection paper on the use of External controls for evidence generation in regulatory decision-making
Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 3 June 2026 - 14:10
Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 6, Status: Authorised
EMA, AMA and African regulatory authorities join forces on Ebola outbreak response
Submitted by Anonymous (not verified) on 3 June 2026 - 13:52
EMA, AMA and African regulatory authorities join forces on Ebola outbreak response
Human medicines European public assessment report (EPAR): Sirturo, bedaquiline, Date of authorisation: 05/03/2014, Revision: 24, Status: Authorised
Submitted by Anonymous (not verified) on 3 June 2026 - 13:10
Human medicines European public assessment report (EPAR): Sirturo, bedaquiline, Date of authorisation: 05/03/2014, Revision: 24, Status: Authorised
EMA’s API general terms and conditions of use - Terms of use
Submitted by Anonymous (not verified) on 3 June 2026 - 11:00
EMA’s API general terms and conditions of use - Terms of use
Meeting summary - Medicine shortages SPOC working party meeting 15 April 2026
Submitted by Anonymous (not verified) on 3 June 2026 - 9:49
Meeting summary - Medicine shortages SPOC working party meeting 15 April 2026
Human medicines European public assessment report (EPAR): Theralugand, lutetium (177Lu) chloride, Date of authorisation: 22/11/2024, Revision: 2, Status: Authorised
Submitted by Anonymous (not verified) on 2 June 2026 - 15:55
Human medicines European public assessment report (EPAR): Theralugand, lutetium (177Lu) chloride, Date of authorisation: 22/11/2024, Revision: 2, Status: Authorised
Questions and answers on the refusal of a change to the marketing authorisation for Hetlioz (tasimelteon) (II-40)
Submitted by Anonymous (not verified) on 2 June 2026 - 15:45
Questions and answers on the refusal of a change to the marketing authorisation for Hetlioz (tasimelteon) (II-40)
Human medicines European public assessment report (EPAR): Pazenir, paclitaxel, Date of authorisation: 06/05/2019, Revision: 11, Status: Authorised
Submitted by Anonymous (not verified) on 2 June 2026 - 15:14
Human medicines European public assessment report (EPAR): Pazenir, paclitaxel, Date of authorisation: 06/05/2019, Revision: 11, Status: Authorised